FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.
What happened
FDA reviewed records the company submitted after FDA's April 28, 2025 request under section 704(a)(4) of the FD&C Act and later correspondence. FDA found significant CGMP violations: no adequate batch release testing for identity, strength, and objectionable microorganisms; no component identity testing for high-risk components; and no process validation. FDA placed all drugs and drug products offered for import from the firm on Import Alert 66-40 on November 12, 2025.
What FDA found
The firm did not test each batch for identity and strength of active ingredients, or for objectionable microorganisms, before release.
21 CFR 211.165(a) and 211.165(b)The firm did not perform at least one identity test on each incoming component, including high-risk components.
21 CFR 211.84(d)(1)The firm did not establish adequate written production and process control procedures and had not performed process validation.
21 CFR 211.100(a)
What FDA wants
FDA tells the firm to respond in writing within 15 working days describing corrective actions and steps to prevent recurrence. FDA also requests specific testing data, including component test results within 30 calendar days, risk assessments, process validation plans, and a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drugs from this manufacturer
- U.S. importers and distributors of OTC drug products
- suppliers of drug components to this manufacturer
This is a summary. Read the original letter on fda.gov.